GlassScriptPhysician profile
Amit Aggarwal
NPI 1326368234
$3,231.28
in general payments reported to CMS, 2019-2025
28 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $213 · 2021: $316 · 2022: $505 · 2023: $648 · 2024: $649 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $729.47 | 2021-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $618.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $288.29 | 2019-2025 | |
| Lilly USA, LLC | $281.55 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $171.45 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $132.89 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $121.28 | 2022-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $101.35 | 2020-2023 | Trelegy Ellipta |
| Amgen INC. | $82.12 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $78.66 | 2019-2023 | Verquvo, Belsomra |
| Exact Sciences Corporation | $67.03 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $60.71 | 2019-2023 | |
| Astellas Pharma US INC | $56.42 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.37 | 2024-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $52.83 | 2023 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.13 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.32 | 2025 | |
| Bausch Health US, LLC | $32.73 | 2019 | |
| Tolmar, INC. | $31.57 | 2025 | Jatenzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.89 | 2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $27.18 | 2022-2023 | Quviviq |
| Smith+Nephew, INC. | $24.84 | 2023 | Collagenase Santyl |
| Biohaven Pharmaceutical Holding Company LTD. | $22.74 | 2022 | |
| Janssen Biotech, INC. | $19.97 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.45 | 2022 | |
| Verity Pharmaceuticals INC. | $15.45 | 2025 | Tlando |
| Vivus LLC | $15.03 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.